Clinical Trial Update: A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

View source ↗

Summary

This post-marketing surveillance trial evaluating cetuximab plus radiotherapy in unresectable locally advanced head and neck squamous cell carcinoma was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck, LA SCCHN | Status: TERMINATED